Pembrolizumab‐Exacerbated Widespread Pigmented Purpuric Dermatosis in an Elderly Patient, a Potential Diagnostic Pitfall Mimicking Pigmented Purpuric Dermatosis‐Like Mycosis Fungoides
Journal of Cutaneous Pathology · 2025
DOI: 10.1111/cup.14841 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Cutaneous Pathology, 2025. Verfasst von Nicole Chang und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Illinois College of Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Mycosis Fungoides, Antibodies, Monoclonal, Humanized, Purpura, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD‐1), programmed cell death ligand 1 (PD‐L1), and cytotoxic lymphocyte‐associated antigen‐4 (CTLA‐4) have revolutionized cancer treatment but are associated with immune‐related adverse events, particularly cutaneous toxicities. We report a rare case of pembrolizumab‐exacerbated pigmented purpuric dermatosis (PPD) in a 77‐year‐old male with a history of metastatic non‐small cell lung cancer. His rash, initially confined to the lower extremities, worsened and became widespread to involve the trunk after pembrolizumab initiation. Histopathology showed perivascular lymphocytic infiltrate with extravasated erythrocytes without vasculitis, compatible with PPD; however, due to some lymphocyte atypia and exocytosis, together with the clinically widespread lesions, there was initial concern for PPD‐like mycosis fungoides (MF). Subsequent T‐cell receptor gene rearrangement studies revealed no monoclonal lymphoid population, and the later resolution of the rash with treatments typical for PPD did not support MF. This represents only the second reported case of ICI‐associated PPD and highlights a potential diagnostic pitfall with histopathology and clinical presentation mimicking PPD‐like MF. Our case contributes to the expanding spectrum of ICI‐related cutaneous reactions and underscores the importance of recognizing inflammatory dermatoses with atypical histopathologic features for dermatologists and dermatopathologists.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Illinois College of Medicine, Chicago, Illinois, USA.
- Department of Dermatology, University of Illinois College of Medicine, Chicago, Illinois, USA.
- ProHealth Care, Waukesha, Wisconsin, USA.
- Department of Dermatology, Venerology and Dermatooncology, Semmelweis University, Budapest, Hungary.
- Great Lakes Pathologists SC, West Allis, Wisconsin, USA.
ORCID-Profile: Nicole Chang, Krisztian Nemeth
Zitieren
APA
Chang, N., Hirsch, Y., Nemeth, K., & Pei, S. (2025). Pembrolizumab‐Exacerbated Widespread Pigmented Purpuric Dermatosis in an Elderly Patient, a Potential Diagnostic Pitfall Mimicking Pigmented Purpuric Dermatosis‐Like Mycosis Fungoides. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.14841
Vancouver
Chang N, Hirsch Y, Nemeth K, Pei S. Pembrolizumab‐Exacerbated Widespread Pigmented Purpuric Dermatosis in an Elderly Patient, a Potential Diagnostic Pitfall Mimicking Pigmented Purpuric Dermatosis‐Like Mycosis Fungoides. Journal of Cutaneous Pathology. 2025. doi:10.1111/cup.14841
BibTeX
@article{Chang2025,
author = {Chang, Nicole and Hirsch, Yoni and Nemeth, Krisztian and Pei, Susan},
title = {Pembrolizumab‐Exacerbated Widespread Pigmented Purpuric Dermatosis in an Elderly Patient, a Potential Diagnostic Pitfall Mimicking Pigmented Purpuric Dermatosis‐Like Mycosis Fungoides},
journal = {Journal of Cutaneous Pathology},
year = {2025},
doi = {10.1111/cup.14841}
}
EUVIMED